ES2196190T3 - Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. - Google Patents

Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.

Info

Publication number
ES2196190T3
ES2196190T3 ES96940406T ES96940406T ES2196190T3 ES 2196190 T3 ES2196190 T3 ES 2196190T3 ES 96940406 T ES96940406 T ES 96940406T ES 96940406 T ES96940406 T ES 96940406T ES 2196190 T3 ES2196190 T3 ES 2196190T3
Authority
ES
Spain
Prior art keywords
metaloproteinasas
matriciales
bifenlico
hydroxamate
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940406T
Other languages
English (en)
Inventor
Stephen W Fesik
James B Summers Jr
Steven K Davidsen
George S Sheppard
Douglas H Steinman
George M Carrera Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2196190T3 publication Critical patent/ES2196190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I), O SU SAL FARMACEUTICAMENTE ACEPTABLE QUE INHIBEN LA METALOPROTEINASAS DE LA MATRIZ Y LA SECRECION DE TNF AL Y SE UTILIZAN EN EL TRATAMIENTO DE SITUACIONES DE ENFERMEDADES INFECCIOSAS. TAMBIEN SE DESCRIBEN COMPOSICIONES INHIBIDORAS DE LAS METALOPROTEINASAS DE LA MATRIZ Y DE LA SECRECION DE TNF AL Y UN PROCEDIMIENTO PARA INHIBIR LAS METALOPROTEINASAS DE LA MATRIZ Y LA SECRECION DE TNF AL .
ES96940406T 1995-11-14 1996-11-13 Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. Expired - Lifetime ES2196190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/555,690 US5665777A (en) 1995-11-14 1995-11-14 Biphenyl hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
ES2196190T3 true ES2196190T3 (es) 2003-12-16

Family

ID=24218248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940406T Expired - Lifetime ES2196190T3 (es) 1995-11-14 1996-11-13 Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.

Country Status (13)

Country Link
US (1) US5665777A (es)
EP (1) EP0874808B1 (es)
JP (1) JP2002504073A (es)
KR (1) KR19990067573A (es)
AT (1) ATE236873T1 (es)
AU (1) AU710666B2 (es)
DE (1) DE69627380T2 (es)
DK (1) DK0874808T3 (es)
ES (1) ES2196190T3 (es)
IL (1) IL123502A0 (es)
MX (1) MX9803809A (es)
PT (1) PT874808E (es)
WO (1) WO1997018188A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890114A1 (en) 1996-03-29 1999-01-13 Lawrence Berkeley National Laboratory Enhancement of nmr and mri in the presence of hyperpolarized noble gases
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
EE04295B1 (et) * 1997-02-27 2004-06-15 American Cyanamid Company N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül-, -sulfinüül- või-sulfonüül-)-3-asendatud-alküülamiidid, -arüülamiidid või -heteroarüülamiididkui maatriksmetalloproteinaasi inhibiitorid
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
NZ501166A (en) * 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000044712A1 (en) * 1999-01-27 2000-08-03 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
WO2001058440A1 (en) * 2000-02-10 2001-08-16 Ono Pharmaceutical Co., Ltd. Remedies for degenerative arthritis
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および/または治療剤
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Il−6産生阻害剤
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
CN102267923B (zh) * 2010-06-04 2015-07-15 台北医学大学 组蛋白去乙酰化酶抑制剂
US20140271465A1 (en) * 2013-03-15 2014-09-18 Mallinckrodt Llc Matrix metalloprotease (mmp) targeted agents for imaging and therapy
ES2784489T3 (es) * 2013-06-27 2020-09-28 Lg Chemical Ltd Derivados de biarilo como agonistas de GPR120
CA2970011C (en) * 2014-12-24 2021-08-03 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
CN109820861B (zh) * 2019-03-13 2021-02-26 湖北科技学院 一种具有抗肿瘤活性的吩噻嗪类衍生物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1548641A (es) * 1967-10-26 1968-12-06
US3755603A (en) * 1970-07-01 1973-08-28 Syntex Corp Biphenylyloxyacetic acids in pharmaceutical compositions
JPS525730A (en) * 1975-07-03 1977-01-17 Nippon Shinyaku Co Ltd Process for preparation of 1,3,5-tri-substituted derivatives
JPS5762239A (en) * 1980-08-26 1982-04-15 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivative
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US5036157A (en) * 1986-03-11 1991-07-30 Burroughs Wellcome Co. Aryl derivatives
ATE120182T1 (de) * 1990-12-03 1995-04-15 Celltech Ltd Peptidylderivate.
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05205730A (ja) * 1992-01-29 1993-08-13 Shin Kobe Electric Mach Co Ltd 薄形鉛蓄電池
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
DE69326612T2 (de) * 1992-07-16 2000-01-13 Chevron Chemical Co. Llc, San Francisco Regenerierung bei niedriger temperatur von reformierkatalysatoren, die durch koks deaktiviert wurden.
US5310121A (en) * 1992-07-24 1994-05-10 Consilium Bulk Babcock Atlanta, Inc. Cold weather bulk stacker/reclaimer apparatus and method
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
JPH08508027A (ja) * 1993-03-16 1996-08-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体
NZ271893A (en) * 1993-08-23 1997-11-24 Immunex Corp Inhibitors of tnf-alpha secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production

Also Published As

Publication number Publication date
DE69627380D1 (en) 2003-05-15
KR19990067573A (ko) 1999-08-25
DK0874808T3 (da) 2003-08-04
AU710666B2 (en) 1999-09-23
MX9803809A (es) 1998-09-30
WO1997018188A1 (en) 1997-05-22
JP2002504073A (ja) 2002-02-05
AU7729696A (en) 1997-06-05
IL123502A0 (en) 1998-09-24
PT874808E (pt) 2003-08-29
EP0874808A1 (en) 1998-11-04
US5665777A (en) 1997-09-09
ATE236873T1 (de) 2003-04-15
EP0874808B1 (en) 2003-04-09
DE69627380T2 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
BR9811099A (pt) Inibidores de urocinase
ES2126094T3 (es) Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma.
MX9308199A (es) Inhibidores de enzima.
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
DK0528858T3 (da) Inhibitorer af dipeptidyl-aminopeptidase type IV
NO944430D0 (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
NO962187D0 (no) Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
RU94015838A (ru) Производные бензофуранил- или бензотиофенилалкан-карбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
AR024138A1 (es) Inhibidores de la proliferacion celular
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
NO922167D0 (no) Aminodukter som korrosjonshemmere
MX9805506A (es) Uso medico novedoso de un inhibidor de la dispepsia relacionada con acido para el tratamiento de sintomas dispepticos.
CO4700430A1 (es) Terapia combinada para inspeccion por vih